Document is current

Article History

Received: 26 January 2018

Revised: 23 August 2018

Accepted: 3 December 2018

First Online: 20 February 2019

Competing interests

: C. Twelves has received honoraria from Roche, Eisai, AstraZeneca, Nektar, Pierre Fabre, and Pfizer. C.I.S., M.G., and L.R. are employees of Eisai Inc. R.P. has received honoraria from Roche, Bristol-Myers Squibb, AstraZeneca, Bayer, Clovis, Vertex, Astex, Novartis, Karus Therapeutics, Mission Therapeutics, and MSD. T.R.J.E. has received research funding from AstraZeneca, Celgene, Eisai, GSK, Roche, Basilea, e-Therapeutics, Immunocore, Vertex, Merck, Daiichi Sankyo, and Bristol-Myers Squibb; has received honoraria from Bristol-Myers Squibb; worked in a consulting or advisory role for Bristol-Myers Squibb, Baxter, Karus Therapeutics, and Eisai; and has received travel and accommodation expenses from, and participated in speakers’ bureaus for, Bristol-Myers Squibb and Celgene. The other authors declare no competing interests.

: This work was supported by the National Institute for Health Research (NIHR) Leeds Clinical Research Facility and by Eisai Ltd, UK. Investigators in Leeds, Newcastle, and Glasgow are supported by the Experimental Cancer Medicine Centre (ECMC) funding from Cancer Research UK, NIHR support from the Department of Health (England), and the Chief Scientist’s Office (Scotland). Editorial support was provided by Oxford PharmaGenesis, Inc, and was funded by Eisai Inc.

: The data in this publication are commercially confidential. Data requests should be made to the Corresponding Author.

: As stated in the article, this study was conducted in accordance with national and local Good Clinical Practice guidelines and the Declaration of Helsinki and was approved by the relevant Institutional Review Board ethics committees. All patients provided written informed consent prior to participating in any study-specific procedures.

: Not applicable. No patient personal identifying data or images are included in this manuscript.